Research
Search
Close
ZHOU Bing
- Doctoral Supervisor, Associate Professor
- Department: Clinical Research Center
- Research Area: Internal medicine
- Research Interests: Mechanisms and Intervention Strategies of Metabolic Dysfunction-Associated Steatotic Liver Disease
- Contact: zhoubing2023@126.com
- Assistant Researcher, Clinical Research Center, Shanghai Sixth People's Hospital, 2024
- Postdoctoral Fellowship, Shanghai Diabetes Institute, Shanghai Sixth People's Hospital, 2021
- MD/PhD in Internal Medicine (Endocrinology & Metabolic Diseases), Zhongshan Hospital, Fudan University, 2018
- MSc in Internal Medicine (Endocrinology & Metabolic Diseases), Sun Yat-sen University, 2014
- Assistant Researcher, Clinical Research Center, Shanghai Sixth People's Hospital
- Zhou Bing, Luo Y, Bi H, Zhang N, Ma M, Dong Z, Ji N, Zhang S, Wang X, Liu Y, Guo X, Wei W, Xie C, Wu L, Wan X, Zheng MH, Zhao B, Li Y, Hu C, Lu Y. Amelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11. Cell Metabolism. 2024 Oct 1;36(10):2228-2244.
- Zhou Bing, Luo Y, Ji N, Hu C, Lu Y. Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis. Nature Metabolism. 2022; 4(9):1185-1201.
- Zhou Bing, Liu C, Xu L, Yuan Y, Zhao J, Zhao W, Chen Y, Qiu J, Meng M, Zheng Y, Wang D, Gao X, Li X, Zhao Q, Wei X, Wu D, Zhang H, Hu C, Zhuo X, Zheng M, Wang H, Lu Y, Ma X. N6-methyladenosine reader protein Ythdc2 suppresses liver steatosis via regulation of mRNA stability of lipogenic genes. Hepatology. 2021; 73(1):91-103.
- Zhou Bing, Jia L, Zhang Z, Xiang L, Yuan Y, Zheng P, Liu B, Ren X, Bian H, Xie L, Li Y, Lu J, Zhang H, Lu Y. The nuclear orphan receptor NR2F6 promotes hepatic steatosis through upregulation of fatty acid transporter CD36. Advanced Science. 2020; 7(21): 2002273.
- Yang Y, Lu J, Liu Y, Zhang N, Luo Y, Ma M, Dong Z, Zhang S, Zheng M, Ruan C, Wan X, Hu C, Lu Y, Ma X, Zhou Bing. Molecular Metabolism. 2024 Nov:89:102030.
- Zhou Bing, Luo Y, Ji N, Ma F, Xiang L, Bian H, Zheng M, Hu C, Li Y, Lu Yan. Promotion of nonalcoholic steatohepatitis by RNA N 6-methyladenosine reader IGF2BP2 in mice. Life Metabolism. June 10, 2022. https://doi.org/10.1093/lifemeta/loac006.
- Liu C, Zhou Bing, Meng M, Zhao W, Wang D, Yuan Y, Zheng Y, Qiu J, Li Y, Li G, Xiong X, Bian H, Zhang H, Wang H, Ma X, Hu C, Xu L, Lu Y. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease. Journal of Hepatology. 2021; 75(1):150-162.
- 01/01/2024–12/31/2025
National Natural Science Foundation of China (Young Scientists Fund), ¥200,000, 82300966
Investigation of the role and mechanism of hepatocyte-derived ORM2 in improving non-alcoholic steatohepatitis by inhibiting Kupffer cell activation.
Role: Principal Investigator - 01/01/2024–12/31/2026
The Ninth Youth Talent Support Project of the China Association for Science and Technology, ¥300,000, 2023QNRC001
Role: Principal Investigator - 09/01/2024–09/30/2029
Shanghai Sixth People's Hospital Talent Recruitment Research Grant, ¥500,000
Research on the mechanisms and intervention strategies of metabolism-associated fatty liver disease.
Role: Principal Investigator - 04/01/2022–03/31/2025
Shanghai Science and Technology Innovation Action Plan (Rising-Star Program), ¥200,000, 22YF1432800
Study on the role and mechanism of nuclear receptor NR2F6 in promoting non-alcoholic steatohepatitis.
Role: Principal Investigator - 11/01/2021–11/30/2023
China Postdoctoral Science Foundation (70th Batch), ¥80,000, 2021M702183
Investigation of the role and mechanism of liver-secreted factor Orosomucoid 2 in non-alcoholic fatty liver disease.
Role: Principal Investigator - 10/01/2021–09/30/2024
Shanghai Sixth People's Hospital Outstanding Youth Training Program, ¥100,000, YNQN202107
Study on the role and mechanism of nuclear receptor NR2F6 in regulating hepatic glucose metabolism.
Role: Principal Investigator
- [Zhou Bing, Ma Mingyue, Bi Hanqi, Zhang Ni, Lu Yan] (2024), “Application of Synaptamide in Treating Hyperlipidemia”, CN202411099992.8
- [Zhou Bing, Bi Hanqi, Ma Mingyue, Luo Yunchen, Lu Yan] (2023), “Application of RPN11 Inhibitor Capzimin in Treating Type 2 Diabetes”, CN202311687576.5.
- [Zhou Bing, Bi Hanqi, Luo Yunchen, Ma Mingyue, Lu Yan] (2023), “Application of RPN11 as a Therapeutic Target for Type 2 Diabetes”, CN202311687582.0.
- [Lu Yan, Zhou Bing, Bian Hua, Li Xiaoying] (2023), “A Protein for Treating Obesity-Associated Fatty Liver”, ZL202011300266.X.
- [Lu Yan, Zhou Bing, Luo Yunchen] (2023), “Application of an RNA in Treating Non-Alcoholic Steatohepatitis”, ZL202111359225.2.
- Patent Commercialization: A Protein for Treating Obesity-Associated Fatty Liver
- Funding Amount: ¥1,500,000
- Conversion Date: December 2021
- Collaborating Institution: Shanghai Impson Biopharmaceutical Technology Co., Ltd.
- Role: Second Inventor
